Dr. Locke Discusses Unanswered Questions With CAR T-Cell Therapy

Video

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses unanswered questions with chimeric antigen receptor T-cell therapy.

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses unanswered questions with chimeric antigen receptor (CAR) T-cell therapy.

There’s a number of remaining challenges with CAR T-cell therapy, one of them being durability of response. Current data show durable responses in 40% of patients with lymphoma. Locke says researchers need to better understand why CAR T-cell therapy doesn’t work for the other 60% of patients. There are some data suggesting there is CD19 loss in a patient who progresses on treatment, though it doesn’t appear to be the case in all patients.

In the ZUMA-1 trial, investigators collected biospecimens from patients and are testing those to better understand mechanisms of resistance to CAR T-cell therapy. Locke says these data should be available shortly. Another next step would be to move CAR T cells to an earlier setting, preferably to the second line. Ongoing randomized trials are testing this question, Locke says.

Recent Videos
Robert Califf, MD, MACC, a cardiologist and former FDA commissioner
Natalie Goedeker, CPNP, on Handling Neuromuscular Gene Therapy at Real-World Sites
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Michael Flanagan, PhD, chief scientific officer at Avidity
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Related Content
© 2025 MJH Life Sciences

All rights reserved.